Laid off from Haemonetics.

As Haemonetics moved Braintree's production to Mexico in 2013, the Labor Department found the shift had contributed to workers' job losses, making them eligible to apply for trade adjustment assistance. Haemonetics later agreed to hand plants in South Carolina and California to buyers, saying some staff would be offered jobs.

What we know about Haemonetics severance and layoffs

  • $84.7 million in charges under the Operational Excellence Program, July 2019 to March 2025
  • About 350 positions in the reduction Haemonetics announced in November 2017
  • 320 job cuts tied to the 2013 plan to close the Braintree plant
  • $17 million estimated for severance and separation benefits in the May 2016 plan
  • 92 jobs on Haemonetics' July 2021 WARN notice for Draper, Utah
  • 75 jobs on the October 2024 notice to close the Covina, California plant

The most recent Haemonetics layoff we've found

Haemonetics had booked $7.9 million in charges under its market and regional alignment initiative by September 26, 2026, including $2.2 million in the six months ended that day, its quarterly report for September 2026 shows.

What Haemonetics layoffs have meant for employees

If you're at Haemonetics, the restructuring its 10-K for fiscal 2026 called "currently ongoing" as of March 28, 2026 was the market and regional alignment initiative. The board approved it in May 2025 to point the company's resources at the markets and regions with the most room for growth, according to the May 2025 8-K. It handed the specific actions to management, and Haemonetics said charges would come as each action was identified and approved. Haemonetics also put a figure on what it hoped to save, about $30 million a year once the initiative was complete. The first actions had been approved in January 2025, the 10-K adds. The Operational Excellence Program had been set up the same way, approved in July 2019 with its details delegated to management, and it closed only in March 2025, after charges of $84.7 million. The two efforts overlapped, since the board approved the first alignment actions in January 2025, before the older program closed in March.

A plan's dollar figures and its count of people who lose jobs are different numbers. That 10-K also lists Haemonetics' restructuring reserves as substantially all severance, other employee costs, inventory reserves and lease termination fees, so a plan's dollar total includes more than pay for people who leave. In 2017 some of the positions Haemonetics counted were open jobs, a spokesperson said, so fewer people left than positions were cut, BioSpace reported. Haemonetics said that plan's cuts would exclude hourly plant workers, certain critical selling and clinical support roles and people on critical, time-bound projects, and would come through voluntary as well as involuntary separations, so some of the people counted chose to leave. When Haemonetics announces a cut, you can ask how many of the eliminated positions were open and how many people are leaving by choice.

When Haemonetics agreed in 2019 to transfer its Union, South Carolina plant, which made saline and sodium citrate for plasma collection, to CSL Plasma, the two companies' joint release said about 200 Haemonetics employees would be given the opportunity to become CSL Plasma employees. GVS, which had agreed in 2020 to take over Haemonetics' Fajardo, Puerto Rico operations, agreed in December 2024 to buy Haemonetics' whole-blood business, the Covina plant included, and Haemonetics said part of the Covina staff would get GVS job offers once the sale was done, MedTech Dive's December report said. Chris Simon, Haemonetics' chief executive, called the Union transfer an important step in the company's asset optimization strategy. If your Haemonetics plant is sold and the buyer offers you a job, that job would be with the buyer, at the buyer's pay and benefits.

While Haemonetics was shifting Braintree's production to Mexico and a contract manufacturer, a move BioSpace reported in May 2013, the Braintree workers were certified under the Trade Act's shift-in-production section, the Labor Department's July 2013 notice shows, with Aerotek and The Alpha Group named beside Haemonetics. That section required that a move of production abroad, or buying from abroad, had contributed importantly to workers losing their jobs. By April 2014 Haemonetics' manufacturing plan also named Sanmina as the contract manufacturer for certain medical equipment and called for a new Haemonetics plant in Malaysia, according to the May 2014 8-K. If your Haemonetics job is moving out of the country, trade adjustment assistance has covered this company's workers before, at Braintree, along with workers of the two other companies the certification named.

Haemonetics gave its headquarters address as Boston on its May 2025 filing, and the two notices our WARN tracker has for the company came from sites in California and Utah. For people at those places, there's more on Massachusetts unemployment benefits for the headquarters, on California unemployment benefits for Covina and on Utah unemployment benefits for Draper.

A sourced history of Haemonetics layoffs

  • May 2025, market and regional alignment initiative

    Haemonetics' board approved it and left the specific actions to management, expecting about $20 million in charges, about half for severance and other employee costs, through fiscal 2027, the May 2025 8-K says.

  • October 2024, Covina, California plant closing notice

    The October 22 letter set the closing for December 31, ending about 75 people's employment if none found other Haemonetics jobs, MedTech Dive reported. After Haemonetics agreed in December to sell the plant to GVS, a spokesperson said it would stay open and some staff would be offered GVS jobs if the sale went through, per MedTech Dive's December report.

  • November 2017, Complexity Reduction Initiative

    Haemonetics said it would end 350 positions by March 2018, about 11 percent of its workforce, BioSpace reported.

  • May 2016, plan to reposition costs and staffing

    Haemonetics committed to reducing its number of employees and finding efficiencies in sales, administration and operations, estimating about $26 million in costs, $17 million of it in severance and separation benefits, its May 2016 8-K says.

  • April 2014, Bothwell, Scotland closing plan and staff cuts

    Haemonetics began consulting employee representatives on closing its Bothwell plant and said it would reduce staff and rationalize its organization globally, its May 2014 8-K says. The widened plan also covered ending manufacturing at Ascoli-Piceno, Italy.

  • May 2013, Braintree, Massachusetts plant closing

    Haemonetics said it would shut the Braintree plant over 12 to 18 months, moving disposables to Tijuana, Mexico, and equipment to a contract manufacturer, and its vice president of investor relations told Mass High Tech the move would bring 320 job cuts, BioSpace reported.

  • 2010, GlobalMed integration plan

    A plan that year included cutting 170 employees and closing facilities in Phoenix and Chicago as Haemonetics folded GlobalMed Technologies into the company after buying it, MassDevice noted, according to BioSpace.

What to do if you're laid off from Haemonetics

Haemonetics layoff and severance questions

What severance has Haemonetics given laid-off employees?

Haemonetics' 2016 and 2025 restructuring filings state severance as plan-wide totals. The May 2016 8-K estimated $17 million for severance and separation benefits, and the May 2025 8-K expected about half of a roughly $20 million initiative to be severance and other employee costs. Neither filing says how those totals were divided among the employees who left.

Is Haemonetics laying off employees in 2026?

Haemonetics' May 2025 8-K and September 2026 10-Q don't establish whether it laid anyone off in 2026. What the September 2026 10-Q does show is continuing restructuring costs under the market and regional alignment initiative, $2.2 million over the six months ended September 26, 2026 and $7.9 million in all. When the board approved that plan, the company expected its charges to run through the end of fiscal 2027, per the May 2025 8-K.

Did Haemonetics close its Covina, California plant?

Haemonetics planned to. Its October 2024 letter set December 31 as the closing date and said employees had the option to look for other jobs at the company, according to MedTech Dive. Once the GVS deal was struck, a spokesperson said in December that the plant would remain open and that some Covina employees would be offered jobs with GVS, according to MedTech Dive's December report.

How many WARN notices has Haemonetics filed?

Our WARN tracker has two. A July 25, 2021 notice listed 92 jobs at Haemonetics in Draper, Utah, and an October 22, 2024 notice listed 75 at the Covina, California plant, with a December 31 closing date that the company's later sale agreement with GVS overtook, according to MedTech Dive.

Sources for this page